{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:23:01Z","timestamp":1748586181711},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/internalmedicine.53.1936","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T12:43:02Z","timestamp":1402922582000},"page":"1291-1298","source":"Crossref","is-referenced-by-count":5,"title":["Characteristics of Tuberculosis in Patients with Rheumatoid Arthritis: A Retrospective Single-center Study"],"prefix":"10.2169","volume":"53","author":[{"given":"Takashi","family":"Ishiguro","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Takayanagi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naho","family":"Kagiyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Sugita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67: 189-194, 2008.","DOI":"10.1136\/ard.2007.072967"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 21: 343-351, 2011.","DOI":"10.1007\/s10165-010-0406-3"},{"key":"3","unstructured":"3. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69: 522-528, 2010."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kaene J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha-neutralizing agent. N Engl J Med 345: 1098-1104, 2001.","DOI":"10.1056\/NEJMoa011110"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yoshinaga Y, Kanamori T, Ota Y, et al. Clinical characteristics of Mycobacterium tuberculosis infection among rheumatoid arthritis patients. Mod Rheumatol 14: 143-148, 2004.","DOI":"10.3109\/s10165-004-0281-x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yamada T, Nakajima A, Inoue E, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65: 1661-1663, 2006.","DOI":"10.1136\/ard.2005.047274"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52: 1986-1992, 2005.","DOI":"10.1002\/art.21137"},{"key":"8","unstructured":"8. Carmona L, Hernández-García C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30: 1436-1439, 2003."},{"key":"9","unstructured":"9. Gómez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48: 2122-2127, 2003."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324, 1988.","DOI":"10.1002\/art.1780310302"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Oken MM, Creech RH, Tomey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.","DOI":"10.1097\/00000421-198212000-00014"},{"key":"12","unstructured":"12. The Japanese Society for Tuberculosis. Guidelines for Clinical Tuberculosis. Nankodo, Tokyo, 2009 (in Japanese)."},{"key":"13","unstructured":"13. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167: 603-662, 2003."},{"key":"14","unstructured":"14. Ubukata M, Takayanagi N, Yanagisawa T, et al. Pulmonary tuberculosis with cerebellar lesion in a patient after anti-TNF-alpha (infliximab) treatment for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi (Journal of the Japanese Respiratory Society) 43: 247-251, 2005 (in Japanese)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50: 372-379, 2004.","DOI":"10.1002\/art.20009"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 69: 380-386, 2010.","DOI":"10.1136\/ard.2008.089276"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 65: 353-361, 2013.","DOI":"10.1002\/acr.21812"},{"key":"18","unstructured":"18. Jeong YJ, Lee KS. Pulmonary tuberculosis: Up-to-date imaging and management. AJR Am J Roentgenol 191: 834-844, 2008."},{"key":"19","unstructured":"19. Takahara M. Clinical evaluation on causes of death in patients with pulmonary tuberculosis. Kekkaku 79: 711-716, 2004 (in Japanese)."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kim DK, Kim HJ, Kwon SY, et al. Nutritional deficit as a negative prognostic factor in patients with miliary tuberculosis. Eur Respir J 32: 1031-1036, 2008.","DOI":"10.1183\/09031936.00174907"},{"key":"21","unstructured":"21. Horita N, Naoki M, Yoshiyama T, et al. Development and validation of a tuberculosis prognostic score for smear positive inpatients: Japanese study. Int J Tuberc Lung Dis 17: 54-60, 2013."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Iikuni N, Inoue E, Tanaka E, et al. Low disease activity state with corticosteroid may not represent 'true' low disease activity state in patients with rheumatoid arthritis. Rheumatology (Oxford) 47: 519-521, 2008.","DOI":"10.1093\/rheumatology\/ken047"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Nakajima A, Inoue E, Tanaka E, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 39: 360-367, 2010.","DOI":"10.3109\/03009741003604542"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345: 1098-1104, 2001.","DOI":"10.1056\/NEJMoa011110"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 72: 37-42, 2013.","DOI":"10.1136\/annrheumdis-2011-200690"},{"key":"26","unstructured":"26. Takeuchi T, Yamanaka H, Inoue E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol 18: 447-454, 2008."},{"key":"27","unstructured":"27. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36: 1185-1206, 2010."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Yamanaka H, Inoue E, Singh G, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol 17: 283-289, 2007.","DOI":"10.1007\/s10165-007-0587-6"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/12\/53_53.1936\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:51:35Z","timestamp":1621446695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/12\/53_53.1936\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.53.1936","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}